Literature DB >> 6299656

Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.

M Ohkawa, A Okasho, I Motoi, S Tokunaga, R Shoda, S Kawaguchi, M Sawaki, M Shimamura, S Hirano, K Kuroda, S Awazu.   

Abstract

The pharmacokinetics of cefotaxime, a new semi-synthetic cephalosporin for injection, was studied in 30 subjects with various degrees of renal function after a single 1-gram intramuscular injection. Serum and urinary concentrations of cefotaxime and desacetyl cefotaxime were determined by high pressure liquid chromatography. The pharmacokinetic parameters of cefotaxime were obtained using a one-compartment open model. The mean serum half-life of the parent compound (cefotaxime), 0.87 h in normal subjects, was prolonged to 2.35 h in hemodialysis patients. There was a significant linear correlation between the elimination rate constant of cefotaxime and creatinine clearance. The mean cumulative urinary recovery of the administered dose in the 24-hour urine was 51.7% as cefotaxime and 25.6% as desacetyl cefotaxime in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299656     DOI: 10.1159/000238166

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Pharmacokinetics of cefotaxime in patients after liver transplantation.

Authors:  E Kuse; P Vogt; B Rosenkranz
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

Review 3.  Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.

Authors:  G L Kearns; R A Young; R F Jacobs
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

4.  Tolerance in patients with terminal renal insufficiency of high doses of cefotaxime.

Authors:  D Höffler; T Wittgens; C Piper
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.

Authors:  C M Paap; M C Nahata; M A Mentser; J D Mahan; S K Puri; J W Hubbard
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

6.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

8.  Cefotaxime pharmacokinetics and treatment of meningitis in neonates.

Authors:  R F Jacobs; G L Kearns
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

9.  Application of Aluminum Hydroxide for Improvement of Label-Free SERS Detection of Some Cephalosporin Antibiotics in Urine.

Authors:  Natalia E Markina; Alexey V Markin
Journal:  Biosensors (Basel)       Date:  2019-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.